2024
Treatment Effect Heterogeneity in Acute Kidney Injury Incidence Following Intravenous Antihypertensive Administration for Severe Blood Pressure Elevation During Hospitalization
Ghazi L, Chen X, Harhay M, Hu L, Biswas A, Peixoto A, Li F, Wilson F. Treatment Effect Heterogeneity in Acute Kidney Injury Incidence Following Intravenous Antihypertensive Administration for Severe Blood Pressure Elevation During Hospitalization. American Journal Of Kidney Diseases 2024 PMID: 39580068, DOI: 10.1053/j.ajkd.2024.09.011.Peer-Reviewed Original ResearchAcute kidney injuryAcute kidney injury incidenceSevere hypertensionIV antihypertensivesAntihypertensive treatmentBlood pressureRisk of acute kidney injuryAbstractText Label="SETTINGS &Blood pressure elevationSevere blood pressure elevationSystolic blood pressureIdentifying treatment optionsAntihypertensive administrationKidney injuryAbstractText Label="RATIONALETreatment optionsAntihypertensive effectBP elevationPressure elevationPatient characteristicsDiastolic BPPatientsKidney failureAntihypertensivesHospital admission
2023
Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia
Blette B, Granholm A, Li F, Shankar-Hari M, Lange T, Munch M, Møller M, Perner A, Harhay M. Causal Bayesian machine learning to assess treatment effect heterogeneity by dexamethasone dose for patients with COVID-19 and severe hypoxemia. Scientific Reports 2023, 13: 6570. PMID: 37085591, PMCID: PMC10120498, DOI: 10.1038/s41598-023-33425-3.Peer-Reviewed Original ResearchConceptsCritical COVID-19Better long-term outcomesCOVID-19Entire trial populationStandardized dosing protocolsMultiple patient characteristicsDose of dexamethasoneLong-term outcomesIL-6 inhibitorsDexamethasone doseSevere hypoxemiaMost patientsPatient characteristicsRespiratory supportDiabetes mellitusClinical outcomesDosing protocolTrial populationTreatment effect heterogeneityPatient featuresPatientsAdditional studiesDexamethasoneDoseMore evidence
2022
Effect of intravenous antihypertensives on outcomes of severe hypertension in hospitalized patients without acute target organ damage
Ghazi L, Li F, Simonov M, Yamamoto Y, Nugent J, Greenberg J, Bakhoum C, Peixoto A, Wilson F. Effect of intravenous antihypertensives on outcomes of severe hypertension in hospitalized patients without acute target organ damage. Journal Of Hypertension 2022, 41: 288-294. PMID: 36583354, PMCID: PMC9799038, DOI: 10.1097/hjh.0000000000003328.Peer-Reviewed Original ResearchConceptsAcute target organ damageTarget organ damageSevere hypertensionOrgan damageIntravenous antihypertensivesBP elevationClinical outcomesMyocardial injuryTarget end-organ damageOverlap propensity scoreSevere BP elevationAcute kidney injuryBlood pressure reductionEnd-organ damageRisk of strokeInpatient hypertensionCardiovascular eventsIndex hospitalizationKidney injuryRetrospective studyHypertensionAntihypertensivesHospitalizationCox modelPatientsSevere inpatient hypertension prevalence and blood pressure response to antihypertensive treatment
Ghazi L, Li F, Chen X, Simonov M, Yamamoto Y, Biswas A, Hanna J, Shah T, Townsend R, Peixoto A, Wilson FP. Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment. Journal Of Clinical Hypertension 2022, 24: 339-349. PMID: 35174627, PMCID: PMC8925013, DOI: 10.1111/jch.14431.Peer-Reviewed Original ResearchConceptsSevere hypertensionBlood pressure responseBP elevationUntreated patientsCox proportional hazards modelRetrospective cohort studyPressure responseProportional hazards modelAntihypertensive treatmentInpatient hypertensionMore comorbiditiesPossible overtreatmentHospitalized adultsCohort studyHypertension prevalenceArterial pressureHospitalized patientsTreatment guidelinesHypertensionGreater rateHazards modelPatientsAntihypertensivesTreatmentAdmission
2021
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance
Wang Y, Jiang Y, Wei D, Singh P, Yu Y, Lee T, Zhang L, Mandl HK, Piotrowski-Daspit AS, Chen X, Li F, Li X, Cheng Y, Josowitz A, Yang F, Zhao Y, Wang F, Zhao Z, Huttner A, Bindra RS, Xiao H, Mark Saltzman W. Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance. Nature Biomedical Engineering 2021, 5: 1048-1058. PMID: 34045730, PMCID: PMC8497438, DOI: 10.1038/s41551-021-00728-7.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryPatient-derived xenograftsTMZ-resistant gliomasTMZ-resistant cellsGlioma cell linesSurvival benefitTemozolomide resistanceChemotherapeutic temozolomideDetectable toxicityTemozolomideOxaliplatin prodrugHuman glioblastomaGenome-wide RNA profilingTranslational strategiesDrugsCell linesGliomasAnticancer drugsMetabolomic analysisGlioblastomaDeliveryDistinct mechanismsRNA profilingMetabolic pathwaysPatients
2017
Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study
Assel MJ, Li F, Wang Y, Allen AS, Baggerly KA, Vickers AJ. Genetic Polymorphisms of CFH and ARMS2 Do Not Predict Response to Antioxidants and Zinc in Patients with Age-Related Macular Degeneration Independent Statistical Evaluations of Data from the Age-Related Eye Disease Study. Ophthalmology 2017, 125: 391-397. PMID: 29032853, PMCID: PMC5820191, DOI: 10.1016/j.ophtha.2017.09.008.Peer-Reviewed Original ResearchConceptsAge-related macular degenerationAdvanced age-related macular degenerationEye Disease StudyGenotype-treatment interactionDisease StudyHigh-risk patientsStandard careAMD progressionBaseline predictorsMacular degenerationTreatment responseGenotype subgroupsAREDS participantsPatientsGenetic polymorphismsSingle nucleotide polymorphismsCategory 1Negative resultsAgePopulation of interestTreatmentMultiple testingProgressionNucleotide polymorphismsAntioxidants